abstract |
The present invention is directed to a combination of MDA-7 protein or MDA-7 encoding nucleic acid with 1) a COX-2 inhibitor such as celecoxib, 2) an Hsp90 inhibitor such as geldanamycin or geldanamycin derivatives or analogs, and 3) vitamins for cancer treatment. E compounds, 4) TNF, such as TNF-alpha, 5) VEGF inhibitors, or 6) inhibitors of IL-10. |